{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-030780","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.403621+00:00","generated_at":"2026-05-26T08:23:13.022887+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Vanda Pharma discloses 2024 bonuses, 2025 salaries, and RSU grants for NEOs","bullets":["CEO Polymeropoulos: 2024 bonus $947,928; 2025 base salary $965,655; target bonus 80%; 450,000 RSUs.","CFO Moran and three SVPs: 2024 bonuses $309,181–$320,040; 2025 base $559,935–$579,600; 45% target; 125,000 RSUs each.","All RSUs vest in four equal annual installments commencing March 1, 2026.","Compensation Committee considered peer-group analysis by Willis Towers Watson before approving."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-030780","json":"https://secwatch.observer/filing/0001193125-25-030780.json","markdown":"https://secwatch.observer/filing/0001193125-25-030780.md","text":"https://secwatch.observer/filing/0001193125-25-030780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000119312525030780/0001193125-25-030780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000119312525030780/d935984d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T08:23:13.022887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}